Frank Nocken/LinkedIn
Nov 16, 2026, 12:52
Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments
Frank Nocken, Independent Consultant for Scientific Innovation Management, shared a post on LinkedIn:
“This year’s Clinical Trials on Alzheimer’s Disease conference program offers a snapshot of the maturation of non-amyloid approaches to address the hard-to-treat neurodegenerative disease.
Starting today, researchers will present data on a range of drug mechanisms, shedding light on how going after tau and other targets may allow physicians to attack Alzheimer’s disease from multiple angles in the years to come.”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 12:44Stefan Prendić: How Intronic Variants Affect Rh Blood Group Antigen Expression
-
Nov 16, 2026, 12:26Samwel Mikaye: Understanding Warfarin and Its Clinical Management
-
Nov 16, 2026, 12:14Sophia Delicou: Ensuring Lifelong Health Beyond Stem Cell Transplantation
-
Nov 16, 2026, 12:06Edward Lee Carter: Has PEPPER Changed the Role of Aspirin in Arthroplasty VTE Prophylaxis?
-
Nov 16, 2026, 11:53Eduardo Ortiz Bello: The Endothelium in Hemostasis and Microcirculation
-
Nov 16, 2026, 11:51Phil Spinella: Advancing Transfusion Medicine Through Collaboration
-
Nov 16, 2026, 11:46Madiha Chowdhury: Behind the Scenes of Blood Transfusion Services
-
Nov 16, 2026, 11:43Nasir Al Allawi: Honouring Excellence in Haematopathology
-
Nov 16, 2026, 11:39Osman El-Maarri: Delete Two Genes from a Cell Line and It Secretes Twice as much Factor VIII